Moderna has been ordered to pay almost £44,000 over the adverts that appeared on X Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024, ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also the company’s first commercial product—has notably struggled to keep its ...

Alnylam lost a similar dispute in a related Moderna case last year. It has filed separate, ongoing patent lawsuits over Pfizer's COVID shots. An Alnylam spokesperson said the company is reviewing the ...

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.

Concerns about the safety and efficacy of mRNA COVID-19 shots have increased after a January 3 report that drug maker Moderna failed to inform the U.S. government of the death of a child during ...

Former COVID-vaccine darling announces job cuts a day before quarterly results are set for release. The stock has tumbled more than 70% in the past year as losses have mounted. In a note to employees ...

The stock price of Moderna has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat. The company reported revenue of $1.86 ...